Bloomberg Law | June 28, 2023
But PhRMA and others face obstacles “showing how the program improperly deprives them of a constitutionally protected private or property right,” said Zachary Baron, an associate director of the Health Policy and the Law Initiative at Georgetown University’s O’Neill Institute.